Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Av-101. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KYNU | Q16719 | 2/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Av-101 SCHEMBL18742668 | 0.93 | KMO (0.51) | KMOKDM4EHIF1ATDP1FLT1 | |
| Av-101 SCHEMBL727370 | 0.93 | KMO (0.51) | KMOKDM4EHIF1ATDP1FLT1 | |
| Av-101 SCHEMBL30852264 | 0.93 | KMO (0.51) | KMOKDM4EHIF1ATDP1FLT1 | |
| Av-101 SCHEMBL30216614 | 0.93 | KMO (0.51) | KMOKDM4EHIF1ATDP1FLT1 | |
| Av-101 SCHEMBL5286788 | 0.93 | KMO (0.51) | KMOKDM4EHIF1ATDP1FLT1 | |
| Av-101 SCHEMBL30733184 | 0.93 | KMO (0.51) | KMOKDM4EHIF1ATDP1FLT1 | |
| SCHEMBL18638182 | 0.82 | ABL1 (0.43) | KMOKDM4EHIF1ATDP1FLT1 | |
| SCHEMBL8397341 | 0.81 | KMO (0.51) | KMOKDM4EHIF1ATDP1GRIK1 | |
| SCHEMBL8397345 | 0.81 | KMO (0.51) | KMOKDM4EHIF1ATDP1GRIK1 | |
| SCHEMBL30852448 | 0.81 | KMO (0.51) | KMOKDM4EHIF1ATDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031800-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. | 2016-02-04 | — | — | US | claimed |
| EP-2970080-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | Vistagen Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152835-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160031800-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2970080-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | Vistagen Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152835-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031800-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | KYNU, KMO, AADAT | KMO 2/4885KDM4E 749/4885HIF1A 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.